Cargando…

Tumour suppressor genes in chemotherapeutic drug response

Since cancer is one of the leading causes of death worldwide, there is an urgent need to find better treatments. Currently, the use of chemotherapeutics remains the predominant option for cancer therapy. However, one of the major obstacles for successful cancer therapy using these chemotherapeutics...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Dulcie, Visser-Grieve, Stacy, Yang, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392105/
https://www.ncbi.nlm.nih.gov/pubmed/22762204
http://dx.doi.org/10.1042/BSR20110125
_version_ 1782237594738753536
author Lai, Dulcie
Visser-Grieve, Stacy
Yang, Xiaolong
author_facet Lai, Dulcie
Visser-Grieve, Stacy
Yang, Xiaolong
author_sort Lai, Dulcie
collection PubMed
description Since cancer is one of the leading causes of death worldwide, there is an urgent need to find better treatments. Currently, the use of chemotherapeutics remains the predominant option for cancer therapy. However, one of the major obstacles for successful cancer therapy using these chemotherapeutics is that patients often do not respond or eventually develop resistance after initial treatment. Therefore identification of genes involved in chemotherapeutic response is critical for predicting tumour response and treating drug-resistant cancer patients. A group of genes commonly lost or inactivated are tumour suppressor genes, which can promote the initiation and progression of cancer through regulation of various biological processes such as cell proliferation, cell death and cell migration/invasion. Recently, mounting evidence suggests that these tumour suppressor genes also play a very important role in the response of cancers to a variety of chemotherapeutic drugs. In the present review, we will provide a comprehensive overview on how major tumour suppressor genes [Rb (retinoblastoma), p53 family, cyclin-dependent kinase inhibitors, BRCA1 (breast-cancer susceptibility gene 1), PTEN (phosphatase and tensin homologue deleted on chromosome 10), Hippo pathway, etc.] are involved in chemotherapeutic drug response and discuss their applications in predicting the clinical outcome of chemotherapy for cancer patients. We also propose that tumour suppressor genes are critical chemotherapeutic targets for the successful treatment of drug-resistant cancer patients in future applications.
format Online
Article
Text
id pubmed-3392105
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-33921052012-07-12 Tumour suppressor genes in chemotherapeutic drug response Lai, Dulcie Visser-Grieve, Stacy Yang, Xiaolong Biosci Rep Review Article Since cancer is one of the leading causes of death worldwide, there is an urgent need to find better treatments. Currently, the use of chemotherapeutics remains the predominant option for cancer therapy. However, one of the major obstacles for successful cancer therapy using these chemotherapeutics is that patients often do not respond or eventually develop resistance after initial treatment. Therefore identification of genes involved in chemotherapeutic response is critical for predicting tumour response and treating drug-resistant cancer patients. A group of genes commonly lost or inactivated are tumour suppressor genes, which can promote the initiation and progression of cancer through regulation of various biological processes such as cell proliferation, cell death and cell migration/invasion. Recently, mounting evidence suggests that these tumour suppressor genes also play a very important role in the response of cancers to a variety of chemotherapeutic drugs. In the present review, we will provide a comprehensive overview on how major tumour suppressor genes [Rb (retinoblastoma), p53 family, cyclin-dependent kinase inhibitors, BRCA1 (breast-cancer susceptibility gene 1), PTEN (phosphatase and tensin homologue deleted on chromosome 10), Hippo pathway, etc.] are involved in chemotherapeutic drug response and discuss their applications in predicting the clinical outcome of chemotherapy for cancer patients. We also propose that tumour suppressor genes are critical chemotherapeutic targets for the successful treatment of drug-resistant cancer patients in future applications. Portland Press Ltd. 2012-04-23 2012-08-01 /pmc/articles/PMC3392105/ /pubmed/22762204 http://dx.doi.org/10.1042/BSR20110125 Text en © 2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited
spellingShingle Review Article
Lai, Dulcie
Visser-Grieve, Stacy
Yang, Xiaolong
Tumour suppressor genes in chemotherapeutic drug response
title Tumour suppressor genes in chemotherapeutic drug response
title_full Tumour suppressor genes in chemotherapeutic drug response
title_fullStr Tumour suppressor genes in chemotherapeutic drug response
title_full_unstemmed Tumour suppressor genes in chemotherapeutic drug response
title_short Tumour suppressor genes in chemotherapeutic drug response
title_sort tumour suppressor genes in chemotherapeutic drug response
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392105/
https://www.ncbi.nlm.nih.gov/pubmed/22762204
http://dx.doi.org/10.1042/BSR20110125
work_keys_str_mv AT laidulcie tumoursuppressorgenesinchemotherapeuticdrugresponse
AT vissergrievestacy tumoursuppressorgenesinchemotherapeuticdrugresponse
AT yangxiaolong tumoursuppressorgenesinchemotherapeuticdrugresponse